Share the post "ADLINE CHEM LAB : Q1 2024 Financial Quarterly Report"
Highlights
- Sales over the Year and quarter:
- Income over the Year and quarter:
- Profit over the Year and quarter: Significant improvement in profitability for ADLINE CHEM LAB LIMITED. Notable increase of 23.17 % in net profit Year to Year, ADLINE CHEM LAB LIMITED’s profitability increased by 180.56 % in this quarter.
- EPS over the Year and quarter: EPS increased by 21.43 % Year to Year. EPS decreased by -383.33 % in previous quarter. Analysis needed for shareholder value.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 0 Cr | Rs. 0 Cr | Rs. 0 Cr | 0 % | 0 % |
| Expenses | Rs. 0.08 Cr | Rs. 0.06 Cr | Rs. 0.1 Cr | + 66.67 % | + 25 % |
| Operating Profit | Rs. -0.08 Cr | Rs. -0.06 Cr | Rs. -0.1 Cr | -66.67 % | -25 % |
| OPM % | 0 % | 0 % | 0 % | 0 % | 0 % |
| Other Income | Rs. 0 Cr | Rs. 0.02 Cr | Rs. 0 Cr | 0 % | 0 % |
| Interest | Rs. 0 Cr | Rs. 0 Cr | Rs. 0 Cr | 0 % | 0 % |
| Depreciation | Rs. 0 Cr | Rs. 0 Cr | Rs. 0 Cr | 0 % | 0 % |
| Profit before tax | Rs. -0.08 Cr | Rs. -0.04 Cr | Rs. -0.1 Cr | -150 % | -25 % |
| Tax % | -0 % | -0 % | -0 % | 0 % | 0 % |
| Net Profit | Rs. -0.08 Cr | Rs. -0.04 Cr | Rs. -0.1 Cr | -150 % | -25 % |
| EPS in Rs | Rs. -0.14 | Rs. -0.06 | Rs. -0.17 | -183.33 % | -21.43 % |
Today, we’re looking at ADLINE CHEM LAB LIMITED’s financial performance for the Q1(Jun 2024).Expenses ticked up slightly by 66.67 % quarter-on-quarter, aligning with the annual rise of 25 %. Operating profit, while down -25 % compared to last year, faced a quarter-on-quarter dip of -66.67 %, signaling a short-term contraction in margins.
Profit before tax declined annually by -25 % but saw a reduction from the preceding quarter by -150 %.
Net profit fell by -25 % year-on-year but witnessed a -150 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual downturn of -21.43 % but a quarterly fall of -183.33 %. In summary, ADLINE CHEM LAB LIMITED’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 0 Cr | Rs. 0 Cr | Rs. 0 Cr | 0 % | 0 % |
| Expenses | Rs. 0.08 Cr | Rs. 0.06 Cr | Rs. 0.1 Cr | + 66.67 % | + 25 % |
| Operating Profit | Rs. -0.08 Cr | Rs. -0.06 Cr | Rs. -0.1 Cr | -66.67 % | -25 % |
| Net Profit | Rs. -0.08 Cr | Rs. -0.04 Cr | Rs. -0.1 Cr | -150 % | -25 % |
| EPS in Rs | Rs. -0.14 | Rs. -0.06 | Rs. -0.17 | -183.33 % | -21.43 % |
In reviewing ADLINE CHEM LAB LIMITED’s 2024(Q1) financial snapshot, key trends emerge, shedding light on the company’s performance.Expenses rose by 25 % compared to the previous year, with a 66.67 % increase quarter-on-quarter. Operating Profit dropped by -25 % annually, and saw a -66.67 % decrease from the last quarter.
Net Profit showed yearly decrease of -25 %, and experienced a -150 % decrease from the previous quarter. Earnings Per Share (EPS) fell by -21.43 % annually, however dipped by -183.33 % compared to the last quarter. In essence, while ADLINE CHEM LAB LIMITED faces strong annual decline indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.
-26
3-Year Profit
0
5-Year Profit
0
10-Year Profit
96.0
Current Price
866
Market Cap
The financial outlook for the company under BSE code 542337 reveals a significant five-year profit of 0 percents. This marks a notable increase to -26 percents over the last three years, indicating a strong upward trend in the company's financial health during this period. However, it's important to note that recent challenges have impacted the company's performance, leading to a trailing twelve-month loss of -8 percents. This sharp decline in profitability is particularly concerning, as the company has also reported no sales across any analyzed timeframe, suggesting a highly unconventional and perhaps risky operational approach. The company's stock prices mirror this financial volatility, with the stock trading at 5 percents over the past five years but experiencing a dramatic drop to 35 percents within the last year. Over a decade, the stock price was at 0 percents, reflecting long-term concerns regarding the company's stability and future outlook. Such performance poses questions about the sustainability of the business and whether it can rebound from these recent setbacks.
Currently valued at ₹866 crore, the company's stock price stands at ₹96.0. Over the years, it has seen significant fluctuations, with its price ranging from ₹139 / 63.0, a reflection of its sensitivity to market conditions and investor sentiment. The stock's Price-to-Earnings (P/E) ratio, currently at , suggests that it is highly valued in comparison to its earnings, possibly indicating strong future growth expectations or a high level of investor confidence. The book value per share is ₹-46.1, which represents the net asset value of the company per share. The dividend yield of 0.00% provides some return to investors, though it may not be the primary attraction for those investing in the stock. The company's Return on Capital Employed (ROCE) is -10.3%, pointing to efficient use of its capital base to generate profits. The Return on Equity (ROE), at %, highlights the profitability for shareholders. The company's financial health is further underscored by its very low debt-to-equity ratio of , signaling conservative financial management. However, the net cash flow is negative at ₹18.3 crore, indicating possible liquidity concerns or heavy investment. The Piotroski score of 3.00 provides a snapshot of its financial stability, while the Graham Number, estimated at ₹, offers an intrinsic value benchmark. With a Price-to-Book (P/B) ratio of , the stock seems to be trading at a premium relative to its book value, which could signal strong market expectations or overvaluation risks.
